Aspire Biopharma Holdings, Inc. (ASBP)

Aspire Biopharma Holdings Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	-	-	-	0.5
Cash & Short-Term Investments	-	-	-	0.5
Inventory	0.25	-	-	-
Other Current Assets	-	-	0.08	0.6
Total Current Assets	1.31	0.15	0.08	1.1
Long-Term Investments	-	-	19.9	299
Other Long-Term Assets	-	-	-	0.08
Total Assets	1.31	0.15	19.98	300.18
Accounts Payable	-	-	0.15	0.18
Accrued Expenses	1.01	-	-	-
Short-Term Debt	4.18	1.27	0.01	-
Other Current Liabilities	1.39	-	0.24	0.12
Total Current Liabilities	6.58	1.27	0.4	0.3
Other Long-Term Liabilities	0.1	-	-	10.81
Total Long-Term Liabilities	0.1	-	-	10.81
Total Liabilities	6.67	1.27	0.4	11.12
Common Stock	0	0	0	0
Additional Paid-in Capital	20.88	1.24	10.96	-
Retained Earnings	-	-	-11.29	-9.94
Total Common Shareholders' Equity	20.88	1.24	-0.32	-9.94
Minority Interest	-	-	19.9	299
Shareholders' Equity	20.88	1.24	19.58	289.07
Total Liabilities & Equity	1.31	0.15	19.98	300.18
Total Debt	4.18	1.27	0.01	0
Net Cash (Debt)	-4.18	-1.27	-0.01	0.5
Net Cash Per Share	-2.79	-1.84	-0.32	12.95
Book Value	20.88	1.24	-0.32	-9.94
Book Value Per Share	13.97	1.79	-8.39	-258.89
Tangible Book Value	20.88	1.24	-0.32	-9.94
Tangible Book Value Per Share	13.97	1.79	-8.39	-258.89

Updated Mar 30, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q